Screening blood donations for Zika virus in the United States is costly with low yield.
Vector-borne diseases represent an increasing problem in the United States, with a more than 2-fold increase in the number of annual reports from 2004 to 2016.
Zika virus RNA is frequently present in the semen of men with symptomatic ZIKV infection and can persist for over 6 months.
Pregnant women may have about a 3-fold longer estimated median detection window for Zika virus RNA in serum.
A vaccine against Zika virus, once available and effectively deployed, may substantially reduce prenatal infections.
A Zika virus vaccine shown to be of moderate to high efficacy in eliminating prenatal infections provides 90% coverage.
Researchers estimated this risk among pregnant women with symptomatic Zika virus infection in French territories in the Americas.
Prompt identification may help reduce the risk for subsequent renal failure and minimize overall disease burden.
Animal model revealed a potential relationship between Zika virus infection and uteroplacental pathology that appears to affect oxygen delivery to the fetus during development.
A total of 5168 noncongenital Zika virus disease cases were reported from US states and the District of Columbia in 2016.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Importance of PrEP for People Involved in Criminal Justice Systems
- Increasing Incidence of Syphilis in People With HIV
- FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents
- Fungal Infections of the CNS: Diagnostic and Treatment Approaches
- Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
- Early Flow Cytometry Predictive of Clinical Deterioration in Sepsis
- Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?
- Hepatitis C Virus Infection Linked to Gut Dysbiosis
- Two Hepatitis C Virus Infection Treatments to Be Discontinued
- Antibiotic Use During Pregnancy May Increase Risk for Childhood Asthma